Interstitial lung disease

Hoag is the First Hospital in Orange County to Perform Breakthrough Treatment Option for Patients with Severe COPD/Emphysema

Retrieved on: 
Tuesday, November 29, 2022
Hoag, U.S. News & World Report, Heart, Diagnosis, Elective surgery, Neuroscience, Lung, OC, Pulmonology, Multimedia, COPD, Life, Respiratory disease, Physician, Patient, Nursing, Interstitial lung disease, Disease, Pulmonary hypertension, Lung cancer, Sleep, Asthma, Cancer, Health, Asa, Walking, Atmosphere, Quality of life, Urinary tract infection, News, American Nurses Credentialing Center, ANCC, Pressure, Diaphragm, Health insurance, Medical imaging, Hospital, Goodman

NEWPORT BEACH, Calif., Nov. 29, 2022 /PRNewswire/ -- Hoag is the first hospital in Orange County to perform a new lung valve treatment on a patient with severe COPD (chronic pulmonary obstructive disease) and emphysema. The procedure has the potential to benefit a number of patients in Orange County who suffer from major quality of life issues related to shortness of breath.

Key Points: 
  • NEWPORT BEACH, Calif., Nov. 29, 2022 /PRNewswire/ -- Hoag is the first hospital in Orange County to perform a new lung valve treatment on a patient with severe COPD (chronic pulmonary obstructive disease) and emphysema.
  • The procedure has the potential to benefit a number of patients in Orange County who suffer from major quality of life issues related to shortness of breath.
  • "We are thrilled to bring this minimally invasive option to patients in Orange County," said Javier Longoria, M.D., the only fellowship-trained interventional pulmonologist in Orange County, who performed the first procedure earlier this month.
  • "Finally having a breakthrough treatment option to help patients with this disease get back to their best self is very exciting," said Dr. Longoria.

VIDA Launches VIDA Intelligence Portal 2.0 to Accelerate Onboarding of Clinical Trial Sites

Retrieved on: 
Monday, November 28, 2022
COVID-19, Hospital, PMDA, Multimedia, Health Canada, Risk, RSNA, COPD, Acquisition, Respiratory disease, Intelligence, Physician, National identity cards in the European Economic Area, Patient, Chronic obstructive pulmonary disease, Biomarker, Interstitial lung disease, Drug development, VIDA, Lung cancer, TGA, Radiology, Asthma, Clinical trial, FDA, Medical imaging, Online shopping, Engineering

CHICAGO, Nov. 28, 2022 /PRNewswire/ -- RSNA 2022 – VIDA Diagnostics, Inc. (VIDA), the leader in imaging intelligence, has announced the availability of VIDA Intelligence Portal 2.0, a major upgrade of its cloud native, AI-enabled Intelligence platform. The newly updated platform drives efficiencies in clinical trial imaging operations by optimizing staff training, image data collection and data quality, curation and management. New digital onboarding features in VIDA Intelligence Portal 2.0 greatly simplify the enrollment process for trial sites.

Key Points: 
  • New digital onboarding features in VIDA Intelligence Portal 2.0 greatly simplify the enrollment process for trial sites.
  • "We are thrilled to see sponsors and trial sites across the globe embracing VIDA Intelligence Portal," said Todd Johnson, VIDA CTO.
  • VIDA has an aggressive roadmap for the VIDA Intelligence Portal, including several new data intelligence services to further accelerate clinical trials.
  • With precise quantitative endpoints and its trial orchestration platform, VIDA Intelligence Portal, VIDA is helping biopharma sponsors save millions in drug development costs.

Bellerophon Provides Clinical Program Update and Reports Third Quarter 2022 Financial Results

Retrieved on: 
Monday, November 14, 2022
FDA, Clinical trial, Trial of the century, Survival, Sarcoidosis, Interstitial lung disease, Data monitoring committee, Paul Fildes, PVR, Actigraphy, DMC, Moderate, Therapy, Patient, Pulmonary hypertension, Hepatic artery proper, Particle-size distribution, Safety, Security (finance), Food and Drug Administration, Annual report, Tesa SA, Research, Ino, Diagnosis, Public expenditure, Food, Pharmaceutical industry, MVPA, Bellerophon

WARREN, N.J., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (Bellerophon or the Company), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the third quarter ended September 30, 2022.

Key Points: 
  • WARREN, N.J., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (Bellerophon or the Company), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the third quarter ended September 30, 2022.
  • REBUILD Phase 3 Study: Phase 3 REBUILD registrational study enrollment of INOpulse for the treatment of fILD is approaching completion.
  • The reduced study size is 140 fILD patients who will be treated with either INOpulse at a dose of iNO45 or a placebo.
  • The Company specifically disclaims any obligation to update any forward-looking statements included in this press release.

Trevi Therapeutics Appoints Pharma Industry Veteran as Chief Medical Officer

Retrieved on: 
Monday, November 14, 2022
GlaxoSmithKline, Idiopathic pulmonary fibrosis, Wilson Therapeutics, IPF, U.S. Securities and Exchange Commission, Security (finance), Nalbuphine, MRCP, University of Edinburgh Medical School, Vicki Belo, Knowledge, Trevi, Royal college, Safety, United Kingdom, University, Interstitial lung disease, Prurigo nodularis, Company, Nasdaq, Therapy, Membership of the Royal Colleges of Physicians of the United Kingdom, Research, Private Securities Litigation Reform Act, Patient, COVID-19, CEO, Risk, Clinical trial, DEA, Chronic cough, Itch, Route of administration, CMO, Drug development, Disease, Cough, Pharmaceutical industry, Medicine, MD, HAVEN, Pfizer

NEW HAVEN, Conn., Nov. 14, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis, today announced the appointment of David Clark, MD, MRCP, as Chief Medical Officer (CMO). Dr. Clark will join Trevi's executive team and be responsible for the strategy and execution of Haduvio's clinical programs.

Key Points: 
  • Most recently, Dr. Clark served as Chief Medical Officer at Allena Pharmaceuticals, leading the Company's clinical development, regulatory and medical affairs teams.
  • Prior to that, he served as Chief Medical Officer for various companies, including Aldeyra Therapeutics, Wilson Therapeutics, and NormOxys.
  • As Chief Medical Officer, Dr. Clark has strategized and supported teams from clinical translation through Phase 3.
  • Dr. Thomas Sciascia, MD, the co-founder of Trevi Therapeutics, previously served as Trevi's Chief Medical Officer and will be transitioning to Chief Science Officer.

aTyr Pharma Announces Third Quarter 2022 Results and Provides Corporate Update

Retrieved on: 
Thursday, November 10, 2022
SAN, ILD, GLOBE, Review, Private Securities Litigation Reform Act, Forward-looking statement, IND, Intellectual property, Investment, ATyr Pharma, Patent, NRP2, FDA, FC, Food, Inflammation, EST, Research, Biology, Risk, Proteomics, Drug discovery, Interstitial lung disease, Interest, Sarcoidosis, SEC, Goal, AARS, Safety, PST, FGFR4, Neuropilin, Food and Drug Administration, Biomarker, Cancer, D, Degenerative disease, Patient, RNA transfection, Therapy, Systemic scleroderma, COVID-19, Pharmaceutical industry, Fine chemical

SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced third quarter 2022 results and provided a corporate update.

Key Points: 
  • Ended the third quarter 2022 with $79.6 million in cash, restricted cash, cash equivalents and investments.
  • SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced third quarter 2022 results and provided a corporate update.
  • Announced the publication of results of the Phase 1b/2a study of efzofitimod in patients with pulmonary sarcoidosis in the peer-reviewed medical journal CHEST.
  • G&A Expenses: General and administrative expenses were $3.6 million for the third quarter of 2022.

aTyr Pharma Announces Publication of Positive Data from Phase 1b/2a Clinical Study of Efzofitimod for the Treatment of Pulmonary Sarcoidosis in the Journal CHEST

Retrieved on: 
Wednesday, November 9, 2022
Quality of life, SAN, GLOBE, Private Securities Litigation Reform Act, Fibrosis, Scar, Forward-looking statement, Manuscript, ATyr Pharma, NRP2, FDA, FC, Inflammation, Research, Biology, Risk, Cough, Department, Granuloma, Death, Interstitial lung disease, Sarcoidosis, Fatigue, SEC, Prognosis, Pulmonology, Fast Track, Safety, Neuropilin, Biomarker, Disease, Degenerative disease, Clinical trial, Cleveland Clinic, Patient, RNA transfection, COVID-19, Medical imaging, Pharmaceutical industry, Dietary supplement

SAN DIEGO, Nov. 09, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the publication in the journal CHEST of positive results from a Phase 1b/2a randomized, double-blind, placebo-controlled clinical trial of its lead therapeutic candidate, efzofitimod, in patients with pulmonary sarcoidosis, a major form of interstitial lung disease. The publication, entitled, “Efzofitimod for the treatment of pulmonary sarcoidosis,” is available on the journal’s website and at: https://doi.org/10.1016/j.chest.2022.10.037.

Key Points: 
  • The publication, entitled, Efzofitimod for the treatment of pulmonary sarcoidosis, is available on the journals website and at: https://doi.org/10.1016/j.chest.2022.10.037 .
  • The ongoing EFZO-FIT study presents the opportunity to evaluate the steroid sparing effects of efzofitimod in a broader clinical trial.
  • The publication of this manuscript marks the first peer-reviewed publication of clinical data for efzofitimod in a major medical journal.
  • The Phase 1b/2a study was a randomized, double-blind, placebo-controlled, multiple-ascending dose clinical trial in 37 patients with pulmonary sarcoidosis.

Zymeworks Provides Corporate Update and Reports Third Quarter 2022 Financial Results

Retrieved on: 
Tuesday, November 8, 2022
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, IND, Partnership, Research, Interstitial lung disease, MBC, PD-1, New, Securities Exchange Act of 1934, Company, Engineering, Security (finance), Federal Lands Jobs and Energy Security Act, Forward-looking statement, NYSE, Conjugation, Manuscript, Securities Act of 1933, Hart–Scott–Rodino Antitrust Improvements Act, U.S. Securities and Exchange Commission, Time, Patient, CEO, Quarter, COVID-19, Depreciation, HER2, Central Time, Legislation, Cancer, Achievement, Janssen, Inc., Growth, Investment, Neutropenia, Workforce, Large-cell lung carcinoma, SVP, Safety, Drug development, Therapy, HR, BeiGene, Fine chemical, Pharmaceutical industry, Cryptocurrency, Vaccine, Bank, Zymeworks, Jazz

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the third quarter ended September 30, 2022.

Key Points: 
  • Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the third quarter ended September 30, 2022.
  • Zymeworks presented encouraging preliminary results in this first-in-human trial evaluating zanidatamab zovodotin in HER2-expressing cancers as a monotherapy.
  • Zymeworks presented an update on its preclinical programs at an Early R&D day in New York City on October 20, 2022.
  • As of September 30, 2022, Zymeworks had $166.2 million in cash resources consisting of cash, cash equivalents and short-term investments.

Trevi Therapeutics to Participate at the Stifel 2022 Healthcare Conference

Retrieved on: 
Tuesday, November 8, 2022
News, Idiopathic pulmonary fibrosis, DEA, Company, Vicki Belo, Trevi, Nalbuphine, Route of administration, IPF, Interstitial lung disease, Conference, Itch, Nasdaq, Chronic cough, Cough, EDT, Therapy, Risk, Safety, Pharmaceutical industry

NEW HAVEN, Conn., Nov. 8, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of serious chronic cough conditions, today announced that Jennifer Good, President and Chief Executive Officer, and Lisa Delfini, Chief Financial Officer, will participate in a fireside chat at the Stifel 2022 Healthcare Conference on Wednesday, November 16, 2022, at 3:35 p.m. ET.

Key Points: 
  • A live audio webcast of the fireside chat will be accessible from the 'Investors & News' section on the Company's website at www.TreviTherapeutics.com .
  • An archived replay of the audio webcast will also be available on the Company's website following the event.
  • Trevi Therapeutics, Inc.is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational oral therapy Haduvio (nalbuphine ER) for the treatment of serious chronic cough conditions.
  • Based on this positive data, Trevi plans to focus future clinical development on chronic cough conditions, including IPF, refractory chronic cough, and interstitial lung diseases (ILDs).

Trevi Therapeutics to Report Q3 2022 Financial Results and Provide a Corporate Update on November 10, 2022

Retrieved on: 
Thursday, November 3, 2022
Company, Nalbuphine, Chronic cough, EDT, Vicki Belo, Cough, Idiopathic pulmonary fibrosis, Safety, Webcast, Route of administration, Therapy, Trevi, IPF, Nasdaq, Review, Conference call, Risk, Itch, DEA, Interstitial lung disease, News, Pharmaceutical industry, Conference

NEW HAVEN, Conn., Nov. 3, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of serious chronic cough conditions, today announced that management will host a conference call and live audio webcast on Thursday, November 10, 2022, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the third quarter ended September 30, 2022.

Key Points: 
  • ET, to provide a corporate update and review the Company's financial results for the third quarter endedSeptember 30, 2022.
  • To participate in the live conference call by phone, please dial (888) 317 6003 (domestic) or (412) 317 6061 (international) and provide access code 4950734.
  • A live audio webcast will be accessible from the 'Investors & News' section on the Company's website at www.TreviTherapeutics.com .
  • An archived replay of the webcast will also be available for 30 days on the Company's website following the event.

New video series highlights the power of caregiving for patients with rare pulmonary fibrosis

Retrieved on: 
Wednesday, November 2, 2022
Awareness, Scar, Interstitial lung disease, Public service announcement, Boehringer Ingelheim, Pulmonary fibrosis, Fibrosis, Yale School of Public Health, Disease, Travel, Degenerative disease, Baylor University Medical Center, PSA, Pulmonology, Patient, PSAS, Caregiver, Residential care, Pharmaceutical industry

"My Life with Pulmonary Fibrosis," is being released during National Family Caregivers Month in November.

Key Points: 
  • "My Life with Pulmonary Fibrosis," is being released during National Family Caregivers Month in November.
  • "My Life with Pulmonary Fibrosis" is a series of videos released during National Family Caregivers Month.
  • Pulmonary fibrosis (PF) is a rare disease that is identified by scarring in the lung tissue.
  • Vick established the organization about 10 years ago because he recognized a need for a close-knit community of patients helping patients.